Takeda Faces Mixed U.S. FDA Report As Advisory Panel Mulls Drug
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceuticals got a mixed response from U.S. FDA for its Contrave (bupropion/naltrexone) weight-loss drug tested in a clinical trial with U.S. co-developer Orexigen Therapeutics